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Purpose
Although randomized clinical trials are considered the
gold standard in biomedicine, they have several limitations
such as experimenting on a sample group under ideal set
forth criteria, creating an environment that does not apply
to daily clinical practice where comorbid conditions are
encountered everyday, and ignoring the differential
response to treatment and treatment-related risk detected
in the study population. This is due in part to the inherent
complexity of the disease process and the heterogeneity
within and between populations – two fundamental prin-
ciples of biology that currently do not receive sufficient
attention in study design. The advent of high throughput
technologies of genomics, proteomics, and deep sequen-
cing has demonstrated the heterogeneous nature of biolo-
gical data. In this paper, we propose to demonstrate how
high throughput data combined with evolutionary-based
analyses could be used to stratify patients prior to starting
the clinical study into groups that share similar traits and
affinities. With this information in hand, participants can
then be randomized to control or treatment groups within
each phyletic clade (or population).
Methods
The method combines omics data with parsimony phylo-
genetics which we developed and named Phylomics®.
Results
This novel approach offers a four-stage clinical trial
design: 1) recruitment from a heterogeneous population
using a wide spectrum inclusion criteria to reflect “real
world” settings; 2) randomization within homogenous
phyletic groups; 3) classification of phyletic groups into
responders and non-responders to drug/intervention; and
4) translation of the clinical trial findings to the clinic. By
knowing the phyletic clade of the patient, the physician
would prescribe the drugs that are most suitable for the
patient, based on his/her membership to the phyletic
clade.
Conclusion
This methodology applies personalized medicine within a
systems biology paradigm that utilizes data heterogeneity,
monitors treatment response and treatment-related risks,
and facilitates a better translation of trials’ results to the
clinic.
Author details
1Georgetown University Medical Center, Washington, D.C., USA. 2National
Institutes of Health, Bethesda, USA.
Published: 12 June 2012
doi:10.1186/1472-6882-12-S1-P115
Cite this article as: Amri et al.: P02.59. Complexity of disease and
population heterogeneity require a rethinking of clinical trial design.
BMC Complementary and Alternative Medicine 2012 12(Suppl 1):P115.
1Georgetown University Medical Center, Washington, D.C., USA
Full list of author information is available at the end of the article
Amri et al. BMC Complementary and Alternative Medicine 2012, 12(Suppl 1):P115
http://www.biomedcentral.com/1472-6882/12/S1/P115
© 2012 Amri et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
